Observational studyEuropean journal of hospital pharmacy : science and practice2023

Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?

Macarena García Trevijano Cabetas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.